These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 34289694)

  • 1. Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.
    Kang Y; Flores L; Ngai HW; Cornejo YR; Haber T; McDonald M; Moreira DF; Gonzaga JM; Abidi W; Zhang Y; Hammad M; Kortylewski M; Aboody KS; Berlin JM
    Bioconjug Chem; 2021 Aug; 32(8):1581-1592. PubMed ID: 34289694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy.
    Dang BN; Duwa R; Lee S; Kwon TK; Chang JH; Jeong JH; Yook S
    J Control Release; 2024 Aug; 372():587-608. PubMed ID: 38942083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
    Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
    Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
    Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
    Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
    Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
    Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
    Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
    J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy.
    Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B
    Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
    Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
    J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery.
    Zhang X; Yue L; Cao L; Liu K; Yang S; Liang S; Liu L; Zhao C; Wu D; Wang Z; Tian R; Rao L
    Acta Biomater; 2024 Sep; 186():369-382. PubMed ID: 39097127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
    Cao L; Dai C; Qin R; Guo Y; Liu J
    Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624
    [No Abstract]   [Full Text] [Related]  

  • 14. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
    Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
    Shayan G; Kansy BA; Gibson SP; Srivastava RM; Bryan JK; Bauman JE; Ohr J; Kim S; Duvvuri U; Clump DA; Heron DE; Johnson JT; Hershberg RM; Ferris RL
    Clin Cancer Res; 2018 Jan; 24(1):62-72. PubMed ID: 29061643
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
    Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
    J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
    Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
    J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
    Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
    Front Immunol; 2021; 12():775761. PubMed ID: 34925348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.